TY - JOUR

T1 - Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

AU - Larsen, Finn Ole

AU - Markussen, Alice

AU - Nielsen, Dorte

AU - Colville-Ebeling, Bonnie

AU - Riis, Lene B

AU - Jensen, Benny V

N1 - © 2017 S. Karger AG, Basel.

PY - 2017

Y1 - 2017

N2 - OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

AB - OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bevacizumab

KW - Camptothecin

KW - Cetuximab

KW - Colorectal Neoplasms

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Female

KW - Fluorouracil

KW - Humans

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Receptor, Epidermal Growth Factor

KW - Retrospective Studies

KW - Survival Rate

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

KW - Journal Article

U2 - 10.1159/000475818

DO - 10.1159/000475818

M3 - Journal article

VL - 93

SP - 191

EP - 196

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -